| HSOS | Hepatic Sinusoidal Obstruction Syndrome |
| Pas | Pyrrolizidine Alkaloids |
| PPAs | Pyrrole-protein adducts |
| GS | Gynura segetum |
| HILI | Herb-Induced Liver Injury |
| DILI | Drug-Induced Liver Injury |
| LSECs | Liver Sinusoidal Endothelial Cells |
| DTSS | Drum Tower Severity Score |
| HSCT | Hematopoietic stem cell transplantation |
| VOD | Veno-occlusive disease |
| IARC | The International Agency for Research on Cancer |
| EFSA | The European Food Safety Authority |
| MHRA | Medicines and Healthcare Products Regulatory Agency |
| DHPAS | Dehydropyrrolizidine alkaloids |
| MMP-9 | Metalloproteinase-9 |
| MMPi | MMP inhibitors |
| DRP1 | Dynamin-related protein 1 |
| MOMP | Mitochondrial outer membrane permeabilization |
| ECM | Excessive deposition of extracellular matrix |
| PT | Prothrombin time |
| APTT | Activated partial thromboplastin time |
| TT | Thrombin time |
| FIB | Fibrinogen |
| DIPS | Direct intrahepatic portocaval shunt |
| TIPS | Transjugular intrahepatic portosystemic shunt |
| Gd-EOBDTPA | Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid |
| RUCAM | Roussel Uclaf Causality Assessment Method |